EPAM enters the final days of August with a striking split personality: the stock has rallied 11.6% on the week and 24% over the past month, while shorts are fleeing and the Street is quietly turning more skeptical.
The most interesting tension this week is a JPMorgan downgrade landing on a stock that has already re-rated sharply higher — a collision between improving sentiment in the price and deteriorating conviction on the Street.
Short sellers are voting with their feet. Short interest has dropped 32% over the past month, falling from roughly 10.6 million shares in late July to just under 7 million now — bringing SI as a percentage of the free float down to 12.6%, the lowest level in that window. The borrow market tells the same story: cost to borrow is a negligible 0.53%, and availability is deep and wide at 372% of outstanding short interest, meaning there are more than three-and-a-half shares available for every one currently borrowed. Shorts are not being squeezed out; they are choosing to leave. Options positioning has also eased — the put/call ratio slipped to 1.02 on Tuesday, meaningfully below its 20-day average of 1.10, suggesting that the demand for downside protection that dominated July has faded alongside the short retreat.
The Street, however, is growing more measured even as the stock climbs. JP Morgan's Puneet Jain cut his rating to Neutral this morning, keeping his $120 target unchanged — a signal that the firm sees the stock as roughly fairly valued after the recent move. That follows a wave of post-earnings target reductions in early August, when Guggenheim trimmed to $140, TD Cowen to $120, Needham to $120, and William Blair went a step further, dropping its Outperform rating entirely. Morgan Stanley's Equal-Weight target was cut to $100. The direction of travel is clear: bulls are still present — ten analysts hold Buy-equivalent ratings versus ten on Hold — but the premium they are willing to assign is shrinking. At $111.85, the stock trades above several freshly-reset targets, a gap that bears watching. Valuation has re-rated alongside the stock; the P/E multiple has expanded 0.83 points over the past 30 days, and price-to-book is up 0.15 over the same stretch. The 12-month forward EPS growth score ranks in the 90th percentile, which is the strongest fundamental signal in the data, but near-term EPS momentum scores sit in the low 30s, suggesting the forward estimates are not yet moving higher.
Institutional ownership adds a genuinely interesting wrinkle. BlackRock added 2.5 million shares as recently as July, taking its stake to nearly 12.9% of the company. Columbia Management added 1.7 million shares through June. Citadel built a position of 1.5 million shares, also through June. These are not passive drifts — they are sizable additions made while the stock was under heavy short pressure and before the current rally. Founder Arkadiy Dobkin's 3.4% stake remains unchanged since March, when he sold roughly $4 million of stock at prices well above current levels.
The Q2 earnings print, released August 6, sent the stock down 11.3% on the day — a painful reaction that triggered the wave of analyst target cuts. The recovery since then has been swift, with the stock clawing back nearly all of that loss and more. The bears' core concern is well-documented: EPAM is trying to convert AI services opportunity into actual revenue while fighting larger competitors, budget pauses, and the lingering drag of its Eastern European delivery footprint. The bulls counter with undervaluation and the scale of the AI services market.
The next earnings event is pencilled in for November 5. Between now and then, the key variable is whether the short-cover rally has run ahead of any real fundamental improvement — and whether the analysts who just reset targets at $110–$120 find reasons to revise upward or simply watch from the sidelines.
See the live data behind this article on ORTEX.
Open EPAM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
